

MC

Attorney's Docket No.: 07039-170002

BOX SEQ
0300
#12

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Jorg J. Goronzy et al. Art Unit : Unknown
Serial No. : 09/723,000 Examiner : Unknown
Filed : November 27, 2000
Title : METHODS AND MATERIALS FOR EVALUATING RHEUMATOID
ARTHRITIS

BOX SEQUENCE

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

The following documents relating to this application are enclosed.

1. Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequences (5 pages);
2. Copy of Notice to Comply with Requirements (1 page);
3. Statement Under 37 CFR §§1.821(f) and (g) (1 page);
4. Verified Statement Under 37 CFR §1.821(f);
5. Paper copy of Sequence Listing (5 pages);
6. Computer-readable copy of Sequence Listing (1 disk); and
7. Postcard.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date:

March 22 2001

J. Patrick Finn III, Ph.D.

Reg. No. 44,109

Fish & Richardson P.C., P.A.
60 South Sixth Street
Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070
Facsimile: (612) 288-9696

60036206.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

March 22, 2001

Date of Deposit

Signature

Jill Huso

Typed or Printed Name of Person Signing Certificate

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Jorg J. Goronzy et al. Art Unit :
Serial No. : 09/723,000 Examiner :
Filed : November 27, 2000
Title : METHODS AND MATERIALS FOR EVALUATING RHEUMATOID
ARTHRITIS

Box Sequence
Commissioner for Patents
Washington, D.C. 20231

VERIFIED STATEMENT UNDER 37 CFR §1.821(f)

I, Jennifer H. Payne, declare that I personally prepared the paper and the computer-readable copy of the Sequence Listing filed herewith for the above-identified application and that the content of both is the same.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of The United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date:

February 23, 2001


Jennifer H. Payne


Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20191725.doc


CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

March 22, 2001
Date of Deposit


Signature

Jill Huso
Typed or Printed Name of Person Signing Certificate



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/723,000	11/27/2000	Jorg J. Goronzy	07039-170002

Mark S Ellinger PhD
Fish & Richardson PC PA
60 South Sixth Street
Suite 3300
Minneapolis, MN 55402

FORMALITIES LETTER



OC000000005692692

Date Mailed: 01/22/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):
 - This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required under 37 CFR 1.821(e).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-1123
- For CRF Submission Help, call (703) 308-4212
- PatentIn Software Program Support
- - For Technical Assistance, call (703) 287-0200
- - To Purchase PatentIn Software, call (703) 306-2600

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE